Comparison · NCT00112385-sae
Etanercept vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Etanercept vs Placebo: serious adverse events. Trial comparisons, record NCT00112385-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00112385-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.273 | 0.0975 | 0.566 | wilson | |
| Risk in group 2 | 0.6 | 0.231 | 0.882 | wilson | |
| Risk difference, group 1 minus group 2 | -0.327 | -0.66 | 0.144 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.455 | 0.137 | 1.51 | log | |
| Odds ratio, group 1 over group 2 | 0.25 | 0.0269 | 2.32 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Etanercept than on Placebo | 3.06 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Etanercept | Subjects randomized to Etanercept will be provided with syringes contain 50 mg and will be injected SQ once a week for 52 wks | 3 | 11 | EG000 |
| Group 2 | Placebo | Subjects will be given syringes containing placebo | 3 | 5 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- from screening to one month after completion of the study (at least 56 wks)
Source ClinicalTrials.gov
Trial
- Title
- A Pilot Study of Etanercept in Dermatomyositis
- NCT number
- NCT00112385
- Phases
- PHASE1
- Conditions
- Dermatomyositis
- Interventions
- Etanercept, Placebo
- Lead sponsor
- Brigham and Women's Hospital
- Results first posted
- 2011-06-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00112385?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00112385-sae